Bookmark Article
Investing in pharmaceutical companies should consider their pipeline strength over current profits, as temporary sales of blockbuster drugs can impact earnings. Pfizer and AbbVie exemplify this, with Pfizer’s Covid vaccine sales boosting profits temporarily, while AbbVie’s Humira faced generic competition but had new drugs in the pipeline. Companies like Novo Nordisk and Eli Lilly are focusing on weight-loss drugs with additional benefits, while AstraZeneca and Merck are prominent in the cancer drug market. Assessing investment potential, Novo and AstraZeneca offer lower risk, Eli Lilly and AbbVie provide reasonable risk/reward profiles, and Merck poses higher risk due to dependency on Keytruda.
Full Article
